Cardiac Risk in Patients with Treatment Naïve, First-Line Medically Controlled and First-Line Surgically Cured Acromegaly in Comparison to Matched Data from the General Population

Abstract

Introduction:

Coronary risk factors in patients with acromegaly after first-line transsphenoidal surgery (TSS) or first-line somatostatine analogue (SSA) treatment have rarely been examined. Aim of this study was an evaluation of cardiovascular risk factors and left ventricular hypertrophy (LVH) in 3 different patient groups with treatment naïve, active (ACT), first-line medically controlled (MED) and first-line surgically treated (SUR) acromegaly and a calculation of the Framingham Weibull Risk Score (FS).

Design:

Retrospective comparative matched case-control study.

Patients & Methods:

40 acromegalic patients (cases aged 45–74 years, 23 men) were matched with respect to age and gender to 200 controls from the general population. 13 patients had treatment-naïve acromegaly (ACT), 12 patients were SSA treated (MED) and 15 patients were operated by TSS (SUR). Coronary risk factors were assessed after 12 months of treatment by interviews and direct laboratory measurements. Only patients normalized for IGF-I in MED and SUR group were included. FS and odds ratios (OR) from multiple conditional logistic regression (matched for age and gender, adjusted for BMI) were calculated.

Results:

Compared to matched controls ACT patients had higher HbA1c levels (6.9±1.4 vs. 5.5±0.7% (p<0.0001)) and an increased prevalence of left ventricular hypertrophy (LVH) (30.8 vs. 3.2% (p=0.007). MED and SUR groups were similar for gender, age, disease duration and IGF-I levels at diagnosis. Compared to matched controls, MED patients had a significantly increased diastolic blood pressure (89±9 vs. 79±11 mmHg (p=0.001), prevalence of LVH (41.7 vs. 1.7% (p<0.0001), prevalence of diabetes mellitus (33.3 vs. 10.0% (p=0.03)), higher HbA1c levels (6.8±1.3 vs. 5.5±0.7% (p=0.0005)) and a higher FS (21.2±9.7 vs. 12.4±7.7% (p=0.002), OR 1.11 [1.02–1.21] (p=0.01)) while in the SUR group only higher prevalences of LVH (40.0 vs. 4.1% (p<0.0001)) and HbA1c levels (6.4±1.2 vs. 5.5±0.8% (p=0.006)) were found compared to controls.

Conclusion:

When comparing treatment naive, medically treated and surgically cured patients with acromegaly to age- and gender-matched subjects from the general population, we have found an increased cardiovascular risk in patients at 12 months after first-line SSA treatment but not in patients after first-line surgery.

Key words

GH Adrenal gland - pituitary adenoma - Cardiovascular risk management - Cardiovascular incidences

• References

• 1 Melmed S. Acromegaly. N Engl J Med 1990; 322: 966-977
• 2 Colao A, Ferone D, Marzullo P et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
• 3 Orme SM, McNally RJ, Cartwright RA et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-2734
• 4 Courville C, Mason VR. The heart in acromegaly. Arch Intern Med 1938; 61: 704-713
• 5 Goldberg MB, Lisser H. Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. J Clin Endocrinol 1942; 2: 477-501
• 6 Hejtmancik MR, Bradfield JY, Herrmann GR. Acromegaly and heart: a clinical and pathologic study. Ann Intern Med 1950; 34: 1445-1456
• 7 Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980; 100: 41-52
• 8 Otsuki M, Kasamaya S, Hiroyasu Y et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001; 54: 791-796
• 9 Cannavò S, Almoto B, Cavalli G et al. Acromegaly and coronaric disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 2006; 91: 3766-3772
• 10 Bogazzi F, Battolla L, Spinelli C et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 2007; 92: 4271-4277
• 11 Schmermund A, Mohlenkamp S, Stang A et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 2002; 144: 212-218
• 12 Stang A, Moebus S, Dragano N et al. Heinz Nixdorf Recall Study Investigation Group . Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. EJE 2005; 20: 489-496
• 13 Barham AH, Goff Jr DC, Chen H et al. Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol 2009; 12: 95-101
• 14 Anderson C. Risk assessment. End of an era. Nature 1991; 353: 289
• 15 Colao A, Auriemma RS, Galdiero M et al. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 2009; 94: 528-537
• 16 Sacca’ L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-573
• 17 Ciulla M, Arosio M, Barelli MV et al. Blood-pressure independent cardiac hypertrophy in acromegalic patients. J Hypert 1999; 17: 1965-1969
• 18 Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24: 272-277
• 19 Colao AM, Marzullo P, Di Somma C et al. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001; 54: 137-154
• 20 Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002; 146: 303-309
• 21 Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414
• 22 Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 2007; 5: 91-96
• 23 Gonzalez C, Rodilla E, Costa JA et al. Cardiovascular risk by Framingham and SCORE in patients 40-65 years old. Med Clin (Barc) 2006; 126: 527-531
• 24 de Visser CL, Bilo HJ, Thomsen TF et al. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253: 553-562
• 25 Berg C, Petersenn S, Lahner H et al. Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators . Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab Aug 2010; 95 (08) 3648-3656
• 26 Akutsu H, Kreutzer J, Wasmeier G et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol May 2010; 162 (05) 879-886
• 27 Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
• 28 Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003; 58: 387-399
• 29 Sudhakar N, Ray A, Vafidis JA. Complications after trans-sphenoidal surgery: our experience and a review of the literature. British Journal of Neurosurgery 2004; 18: 507-512
• 30 Ciric I, Ragin A, Baumgartner C et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40: 225-236
• 31 Cappabianca P, Cavallo LM, Colao A et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. Journal of Neurosurgery 2002; 97: 293-298
• 32 Mortini P, Losa M, Barzaghi R et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005; 56: 1222-1233
• 33 Newman CB, Melmed S, Snyder PJ et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients – a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2768-2775
• 34 Cozzi R, Attanasio R, Montini M et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. Journal of Clinical Endocrinology and Metabolism 2003; 88: 3090-3098
• 35 Mercado M, Borges F, Bouterfa H et al. A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 2007; 66: 859-868
• 36 Lamberts SW, Uitterlinden P, Verschoor L et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1985; 313: 1576-1580
• 37 Kasayama S, Otsuki M, Takagi M et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52: 549-555
• 38 Ronchi CL, Varca V, Beck-Peccoz P et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006; 91: 121-128
• 39 Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-529
• 40 Mazziotti G, Porcelli T, Bogazzi F et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. EJE 2011; 164: 341-347
• 41 Erbel R, Möhlenkamp S, Jöckel KH et al. Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study. Dtsch Arztebl Int 2008; 105 (1–2) 1-8
• 42 Erbel R, Möhlenkamp S, Lehmann N et al. Heinz Nixdorf Recall Study Investigative Group . Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis Apr 2008; 197 (02) 662-672